@article{dd33eee5762b46619e9d62690dd2090f,
title = "HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation",
abstract = "Pathogen-specific CD8+ T cell responses restricted by the nonpolymorphic nonclassical class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections. The natural HLA-E ligand is a signal peptide derived from classical class Ia HLA molecules that interact with the NKG2/CD94 receptors to regulate natural killer cell functions, but pathogen-derived peptides can also be presented by HLA-E. Here, we describe five peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited HLA-E-restricted CD8+ T cell responses in convalescent patients with coronavirus disease 2019. These T cell responses were identified in the blood at frequencies similar to those reported for classical HLA-Ia-restricted anti-SARS-CoV-2 CD8+ T cells. HLA-E peptide-specific CD8+ T cell clones, which expressed diverse T cell receptors, suppressed SARS-CoV-2 replication in Calu-3 human lung epithelial cells. SARS-CoV-2 infection markedly down-regulated classical HLA class I expression in Calu-3 cells and primary reconstituted human airway epithelial cells, whereas HLA-E expression was not affected, enabling T cell recognition. Thus, HLA-E-restricted T cells could contribute to the control of SARS-CoV-2 infection alongside classical T cells.",
keywords = "Humans, SARS-CoV-2, COVID-19, CD8-Positive T-Lymphocytes, Down-Regulation, Histocompatibility Antigens Class II, Virus Replication, Antibodies",
author = "{ISARIC4C Investigators} and Hongbing Yang and Hong Sun and Simon Brackenridge and Xiaodong Zhuang and Wing, {Peter A C} and Max Quastel and Lucy Walters and Lee Garner and Beibei Wang and Xuan Yao and Felce, {Suet Ling} and Yanchun Peng and Shona Moore and Peeters, {Bas W A} and Margarida Rei and {Canto Gomes}, Joao and Ana Tomas and Andrew Davidson and Semple, {Malcolm G} and Turtle, {Lance C W} and Openshaw, {Peter J M} and Baillie, {J Kenneth} and Mentzer, {Alexander J} and Paul Klenerman and Persephone Borrow and Tao Dong and McKeating, {Jane A} and Gillespie, {Geraldine M} and McMichael, {Andrew J}",
note = "Funding Information: Acknowledgments:W ethankthepatientsandtheirlovedoneswhovolunteeredtocontribute tothisstudyatoneofthemostdifficulttimesintheirlivesandtheresearchstaffateachhospital who recruited patients at personal risk during the most extreme conditions ever witnessed in U.K.hospitals.ThisworkalsousesdataprovidedbypatientsandcollectedbytheNHSaspartof theircareandsupport#DataSavesLives.W earegratefultoC.Rubioforexcellenttechnical assistanceandW .James(SirWilliamDunnSchoolofPa thology ,UniversityofOxford)forthe provisionofSARS-CoV-2strains.Calu-3cellswerepro vided byAndersonRyan(Oncology Department,UniversityofOxford).A549-A CE2 cellswerepro vided byAlfredoCastello(CVR, UniversityofGlasgow).ThepHLSec-A vitag3 vectorwasagiftfromR.Aricescu(MRCLMB, Cambridge). W e follow the University of Oxford{\textquoteright}s “Good research conduct guidance on publication,authorshipandpeerreview”(https://researchsupport.admin.ox.ac.uk/governance/ integrity/publication)andguidelinesissuedbyICMJE.Theviewsexpr essed arethoseofthe author(s)andnotnecessarilythoseoftheNHS,theNIHR,theDepartmentofHealth,orPublic HealthEngland.Funding:ThisworkwassupportedbygrantsfromtheBillandMelindaGates Foundation(BMGFOPP1133649);theChineseAcademyofMedicalSciences(CAMS)Innovation FundforMedicalSciences(CIFMS2018-I2M-2-002);theU.K.MedicalResearchCouncil(MRC)– fundedHumanImmunologyUnit,MRCprojectgrantMR/R022011/1;theOxfordshireHealth Services Research Committee reference 1308, NIHR Biomedical Research Centre, Oxford; and theDepartmentofHealthandSocialCareUKRI/NIHRCOVID-19RapidResponseGrant(CO VI9-RECPLA). This research was funded in part by W ellcome Trust grant 109965MA, a cOAlition S organization.TheauthorswillmaketheAuthorAcceptedManuscript(AAM)versionavailable under a CC BY public copyright license. H.Y . and S.B. received support from the Chinese AcademyofMedicalSciences(CAMS)InnovationFundforMedicalScience(CIFMS),China (grantnumber:2018-I2M-2-002).H.S.issupportedbyCIFMS2018-I2M-2-002andtheChina ScholarshipCouncil.J.A.M.issupportedbyaW ellcome TrustInvestigatorA ward(IA)200838/Z/ 16/Z,L.C.W .T .holdsaW ellcome Trustfellowship(205228/Z/16/Z)andisalsosupportedbythe NationalInstituteforHealthResearch(NIHR)HealthProtectionResearchUnit(HPRU)in EmergingandZoonoticInfections(NIHR200907)atUniversityofLiverpoolinpartnershipwith PublicHealthEngland(PHE),incollaborationwithLiverpoolSchoolofTr opical Medicineand UniversityofOxford.A.J.MentzerisanNIHRAcademicClinicalLecturer,andA.J.McMichaeland P .B. areJennerInstituteinvestigators.P .J.M.O. issupportedbyaNIHRSeniorInvestigatorA ward (awardno.201385).A.D.issupportedbyU.K.MRCgrantMR/V027506/1.P .K. wasfundedby W ellcome grant222426/Z/21/Z.ISARIC4CissupportedbygrantsfromtheMedicalResearch Council(grantMC_PC_19059),theNIHR(aw ard no.CO-CIN-01),andbytheNIHRHealth ProtectionResearchUnit(HPRU)inEmergingandZoonoticInfectionsatUniversityofLiverpool inpartnershipwithPublicHealthEngland(PHE),incollaborationwithLiverpoolSchoolof Tropical Medicine and University of Oxford (award no. 200907), NIHR HPRU in Respiratory InfectionsatImperialCollegeLondonwithPHE(awardno.200927),W elcome Trus tand DepartmentforInternationalDevelopment(215091/Z/18/Z),andtheBillandMelindaGates Foundation(OPP1209135);theLiverpoolExperimentalCancerMedicineCentre(grant reference: C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (IS-BRC-1215-20013),andtheNIHRClinicalResearchNetworkprovidedinfrastructuresupportfor thisresearch.Authorcontributions:H.Y ., H.S.,G.M.G.,J.A.M.,andA.J.McMichaeldesignedand performedtheexperiments,analyzedthedata,andwrotethemanuscript.P .B. andP .K. critically reviewed the manuscript and analyzed data. S.B., L.W ., and G.M.G. predicted and tested HLA-E bindingpeptides.S.B.andL.G.conductedtheSCTassays.M.Q.performedDSFassaysand generatedHLA-Eproteins.X.Z.andP .A.C.W .conductedSARS-CoV-2viralinfectionintheCL3 laboratory.X.Y ., S.L.F ., Y .C.P ., andT .D. contributedtoTCRsequencingandanalysis.B.W ., Y .C.P ., andT .D. generatedtheA*24CD8+Tcellclone.M.R.,J.C.G.,A.T ., andB.W .A.P .madeTCR transductants.S.M.,M.G.S.,L.C.W .T ., P .J.M.O., J.K.B.,A.J.Mentzer,P .K., andISARIC4Cprovided samples from patients with CO VID-19. All authors read and approv ed the manuscript. Competinginterests:A.J.McMichael,S.B.,H.Y ., M.Q.,H.S.,L.W ., M.R.,andG.M.G.areinventors on patents held by University of Oxford related to this report. These are patent PCT/GB2022/ 051383forHLA-Ebindingepitopediscovery(A.J.McMichael,S.B.,L.W ., andG.M.G.),patent WO2022144556A1PCT/GB2021/05342forstabilizingpeptideHLA-Ecomplexes(A.J. McMichael,M.Q.,L.W ., andG.M.G.),patentWO2022118030A1PCT/GB2021/053155forHLA-E– specificTcellreceptors(A.J.McMichael,H.Y ., H.S.,M.R.,G.M.G.,andS.B.),andpatent WO2022060893AB,coheldbyDukeUniversityandUniversityofOxfordforantibodiesthat targetHLA-E–hostpeptidecomplexesandusesthereof(A.J.McMichael,G.M.G.,S.B.,andL.W .). A.J.McMichaelisalsoaninventoronpatentJP2013006244AonpeptideHLA-Epeptidebinding. A.J.McMichaelreceivesroyaltiesforapatentonHLA-Ebinding.A.J.McMichaelisacofounderof E-BiotherapyLtd.,whichiscurrentlydormant.Dataandmaterialsavailability:Alldata neededtoevaluatetheconclusionsinthepaperarepresentinthepaperortheSupplementary Materials.Newlycreatedmaterialsusedinthisprojectareavailablefromthecorresponding authors upon request. Raw sequencing data are available at Mendeley Data (doi: 10.17632/ fcjsf59zpt.1)https://data.mendeley.com/datasets/fcjsf59zpt. Funding Information: This work was supported by grants from the Bill and Melinda Gates Foundation (BMGF OPP1133649); the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2018-I2M-2-002); the U.K. Medical Research Council (MRC)–funded Human Immunology Unit, MRC project grant MR/R022011/1; the Oxfordshire Health Services Research Committee reference 1308, NIHR Biomedical Research Centre, Oxford; and the Department of Health and Social Care UKRI/NIHR COVID-19 Rapid Response Grant (COVI9-RECPLA). This research was funded in part by Wellcome Trust grant 109965MA, a cOAlition S organization. The authors will make the Author Accepted Manuscript (AAM) version available under a CC BY public copyright license. H.Y. and S.B. received support from the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002). H.S. is supported by CIFMS 2018-I2M-2-002 and the China Scholarship Council. J.A.M. is supported by a Wellcome Trust Investigator Award (IA) 200838/Z/ 16/Z, L.C.W.T. holds a Wellcome Trust fellowship (205228/Z/16/Z) and is also supported by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and University of Oxford. A.J. Mentzer is an NIHR Academic Clinical Lecturer, and A.J. McMichael and P.B. are Jenner Institute investigators. P.J.M.O. is supported by a NIHR Senior Investigator Award (award no. 201385). A.D. is supported by U.K. MRC grant MR/V027506/1. P.K. was funded by Wellcome grant 222426/Z/21/Z. ISARIC4C is supported by grants from the Medical Research Council (grant MC_PC_19059), the NIHR (award no. CO-CIN-01), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and University of Oxford (award no. 200907), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award no. 200927), Welcome Trust and Department for International Development (215091/Z/18/Z), and the Bill and Melinda Gates Foundation (OPP1209135); the Liverpool Experimental Cancer Medicine Centre (grant reference: C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (IS-BRC-1215-20013), and the NIHR Clinical Research Network provided infrastructure support for this research. Publisher Copyright: Copyright {\textcopyright} 2023 The Authors, some rights reserved.",
year = "2023",
month = jun,
day = "30",
doi = "10.1126/sciimmunol.abl8881",
language = "English",
volume = "8",
pages = "1--17",
journal = "Science Immunology",
issn = "2470-9468",
publisher = "American Association for the Advancement of Science",
number = "84",
}